Sham
6
20M
6
0.06
1
2
- Areas of investment
Summary
Sham appeared to be the Corporate Investor, which was created in 1927. The main department of described Corporate Investor is located in the Lyon. The company was established in Europe in France.
The top amount of exits for fund were in 2018. Comparing to the other companies, this Sham performs on 21 percentage points more the average number of lead investments. The fund is constantly included in less than 2 investment rounds annually. The high activity for fund was in 2013. Deals in the range of 5 - 10 millions dollars are the general things for fund.
The typical case for the fund is to invest in rounds with 3-4 participants. The meaningful sponsors for the fund in investment in the same round are Sofimac Partners, Omnes Capital, Octalfa. In the next rounds fund is usually obtained by Bpifrance, Qualcomm Ventures, Lundbeckfonden Ventures.
We can highlight the next thriving fund investment areas, such as Biotechnology, Information and Communications Technology (ICT). Among the most popular portfolio startups of the fund, we may highlight Glycode, EyeTechCare, Biom'Up. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - France. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager.
Investments analytics
Analytics
- Total investments
- 6
- Lead investments
- 1
- Exits
- 2
- Rounds per year
- 0.06
- Investments by industry
- Medical Device (5)
- Health Care (5)
- Biotechnology (2)
- Software (2)
- Medical (2) Show 8 more
- Investments by region
-
- France (5)
- United States (1)
- Peak activity year
- 2012
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 14
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Amolyt Pharma | 31 Jul 2019 | Health Care, Medical, Therapeutics | Early Stage Venture | 79M | Rhone-Alpes, Écully, France |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.